Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ziprasidone in the Treatment of Borderline Personality Disorder

This study has been completed.
Sponsor:
Collaborators:
Ministry of Health, Spain
REM-TAP Network
Pfizer
Information provided by:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ClinicalTrials.gov Identifier:
NCT00635921
First received: March 11, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2006
  Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
No publications provided by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):